Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that human placenta treatment may promote hair regrowth in chemotherapy-induced alopecia by inhibiting apoptosis and encouraging hair follicle proliferation in a mouse model.

This study identified 19 genes targeted by 29 potential drugs for topical treatment of chemotherapy-induced alopecia, suggesting avenues for drug repositioning in pharmaceutical research.

This article discusses chemotherapy-induced alopecia and its significant psychological impact on cancer patients, noting that some may even refuse treatment due to fear of hair loss.

This study introduced and validated new spectrophotometric methods to simultaneously determine finasteride and tadalafil in Entadfi™ capsules with high sensitivity and without interference from excipients.

This study found that coadministration of tadalafil and finasteride improved lower urinary tract symptoms and erectile function in men with benign prostatic hyperplasia better than finasteride alone over 26 weeks.

In a mouse model of chemotherapy-induced alopecia, this study found that inhibiting the protein S100A8 with paquinimod alleviated hair loss and reduced oxidative stress and ferroptosis, suggesting a potential therapeutic strategy for managing this side effect in chemotherapy patients.

In this study, manual cold capping was found to be effective in minimizing chemotherapy-induced alopecia, with 92.1% of patients retaining 50% or more of their hair, although effectiveness varied with different chemotherapy regimens.

Platelet-rich plasma doesn't prevent hair loss from chemotherapy, and mononuclear cells only help against hair loss from one specific chemotherapy drug.

Cancer treatments can cause skin-related side effects that may affect patient quality of life and require changes in treatment.

This study found that scalp cooling did not entirely prevent permanent chemotherapy-induced alopecia in breast cancer patients, with a significant risk observed among postmenopausal women undergoing anthracycline and taxane-based chemotherapy.

This chapter provides an overview of chemotherapy-induced alopecia, discussing its biological and clinical aspects, current experimental models and treatments, and calls for improved understanding to prevent and manage it.

Tailored treatment is crucial for elderly men with BPH due to potential risks and benefits of medications.

This paper reviews scalp cooling as an effective method for preventing chemotherapy-induced alopecia, highlighting recent trials that demonstrate its ability to preserve and regrow hair, thus improving patient well-being.

This study found that ALRN-6924, a clinical-stage dual inhibitor, can selectively protect human scalp hair follicles from paclitaxel-induced toxicity and damage by inducing transient cell cycle arrest in healthy cells without affecting cancer cells, potentially reducing chemotherapy-induced alopecia.

The document concludes that scalp cooling and treatments like minoxidil can help manage hair loss from cancer therapy.

This review summarizes 19 patents filed since 2000 for treating or preventing chemotherapy-induced alopecia, but reports no new clinical findings.

This literature review identified that phosphodiesterase 5 inhibitors, such as Tadalafil, are highly effective in improving lower urinary tract symptoms associated with benign prostatic hyperplasia, while the efficacy of saw palmetto remains inconsistent.

In this study, researchers investigated genetic variants in pharmacogenes affecting tadalafil and finasteride pharmacokinetics, finding fed volunteers had higher drug exposure than fasting individuals, but genetic variation did not significantly impact pharmacokinetics after correcting for multiple comparisons.

This study found that young men with post-finasteride syndrome may experience erectile dysfunction due to potential histologic changes in penile tissue, despite having normal penile Doppler hemodynamics.

This abstract is a website placeholder and reports no research findings or results; it contains navigation and policy information for JAMA Dermatology.

This review discusses the psychological and social challenges of chemotherapy-induced alopecia and reports no clinical results; the authors suggest that hair loss concerns can significantly impact patient treatment decisions.

In this study, the combination of scalp cooling therapy and a scalp lotion containing DHL-HisZnNa demonstrated a 91.3% hair recovery rate among breast cancer patients undergoing certain chemotherapy regimens, with no serious adverse events reported.

This review highlights emerging evidence that chemotherapy-induced alopecia may be driven by immune mechanisms similar to alopecia areata, involving hair follicle immune privilege collapse, and evaluates Janus kinase inhibitors as potential treatments, while cautioning about their immunosuppressive risks in cancer patients.

This study found that both scalp cooling systems and chemical cooling caps effectively reduced chemotherapy-induced alopecia in early breast cancer patients, with scalp cooling showing better early efficacy but chemical cooling providing greater psychological and quality of life benefits.

The researchers reported that administration of the antioxidant compound TS-13 in mice with chemotherapy-induced alopecia accelerated hair regrowth, although it did not fully prevent chemotherapy-related hair loss, suggesting TS-13 may aid in managing hair loss without negating the cancer treatment's effectiveness.

This narrative systematic review reports that gel-based, cryogel, and silicone-based cooling caps offer cost-effective and environmentally sustainable alternatives to traditional machine-operated systems for preventing chemotherapy-induced hair loss, particularly benefiting low-income and low-resource settings.

This study found that the highest antioxidant-activity formulation of the RENTT herbal combination effectively stimulated hair growth in mice and may serve as a natural therapy for chemotherapy-induced alopecia.

This study found that an optimal combination of ethnomedicinal extracts from East Nusa Tenggara, Indonesia, significantly increased hair length in mice, suggesting potential as a natural agent for hair growth through antioxidant mechanisms.

This study found that while exosome therapy shows promise for treating AGA, AA, and CIA, its integration into routine practice will depend on rigorous clinical trials and standardized manufacturing and regulatory practices to ensure safety and reproducibility.

In this murine study, researchers found that topical treatment with Philippine stingless bee propolis increased folliculogenesis, epidermal thickness, and melanogenesis, but not hair length, potentially supporting hair follicle regeneration and melanocyte function in chemotherapy-induced alopecia models.